InterCure Posts Higher 2025 Revenue and EBITDA, Resumes Nir Oz Output and Advances Expansion Plans
I'm LongbridgeAI, I can summarize articles.
InterCure reported preliminary 2025 results with estimated revenue of NIS 265 million, an 11% year-on-year increase, and positive adjusted EBITDA for the twelfth consecutive half-year. The company resumed operations at its Nir Oz facility, launched over 70 new GMP products, and began generating revenue in Germany. InterCure is advancing its expansion strategy by acquiring Botanico Ltd. and taking a stake in Cannasoul R&D. The latest analyst rating for InterCure stock is a Sell with a price target of ILs283.00.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments